

# VBC Release Highlights

April 5, 2024

Practice Insights<sup>SM</sup> is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

## MIPS Quality Measures Dashboard

The dashboard has also been updated to reflect the below refinement(s) for:

Measure	Description	
MIPS #134: Preventive Care and Screening	The 2024 measure specification no longer considers a diagnosis of depression as an exclusion. The exclusion criteria will be updated to reflect this. The denominator exclusion reason will be updated to, "Patients who have ever been diagnosed with bipolar disorder".	Practices may notice a slight difference due to patients with a diagnosis of depression no longer being excluded.

## MIPS Promoting Interoperability Dashboard

On Monday, April 8, 2024, YTD 2024 data can be accessed from the Time Period dropdown, and, by default, the dashboard will show the latest 90-day period in 2024.

## Status of Dashboard Updates for 2024

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2024 requirements. The measures listed below either have no 2024 update required or have been updated.

Measure	Description
<b>MIPS Quality Measures Dashboard</b>	
#128	BMI (This measure is no longer a MIPS Traditional Measure)
#130	Current Medications
#134	Preventive Care and Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#374	Closing the Referral Loop
#462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center